Guideline |
Population |
Goal blood pressure (mmHg) |
Initial treatment options |
2024[2] |
General |
120–129/70–79 |
BP >140/90: Two from different classes: preferably RAS-inhibitor (ACEI or ARB) with either thiazide diuretic/thiazide-like diuretic or dihydropyridine CCB. |
2023[3] |
General age <65
General age 65–79
General age ≥80 |
<130/80
<140 SBP
<150 SBP |
BP <150/95: Lifestyle changes
BP ≥150/95 or has CVD risk factors or failed lifestyle changes: Two from different classes: thiazide-type diuretic, ACEI/ARB, and/or CCB |
2022[4][5] |
General |
<140/90 |
BP >140/90 and low-risk for CVD: Lifestyle changes
BP >140/90 and CVD risk factors or failed lifestyle changes: monotherapy with thiazide-type diuretic, ACEI/ARB, and/or CCB
BP >160/100: Two from different classes: thiazide-type diuretic, ACEI/ARB, and/or CCB |
2021[6] |
General
High CVD risk, diabetes or CKD
Previous CVD |
<140/90
<130 SBP
<130 SBP |
BP ≥140/90 and low-risk for CVD: Two from different classes: thiazide-type diuretic, ACEI/ARB, and/or CCB
SBP ≥130 and CVD risk factors, diabetes or CKD: Two from different classes: thiazide-type diuretic, ACEI/ARB, and/or CCB
SBP ≥130 and previous CVD: Two from different classes: thiazide-type diuretic, ACEI/ARB, and/or CCB |
2021[7] |
CKD
with kidney transplant |
<120 SBP
<130/80 |
CKD: ACEI/ARB
Kidney transplant: ARB or CCB |
2020[8] |
General
Age <65
Age ≥65 |
<140/90 (reduction by at least 20/10)
<130/80
<140/90 |
BP >140/90 and low-risk for CVD: Lifestyle changes
BP >140/90 and CVD risk factors or failed lifestyle changes: monotherapy with thiazide-type diuretic, ACEI/ARB, and/or CCB
BP >160/100: Two from different classes: thiazide-type diuretic, ACEI/ARB, and/or CCB |
2020[9] |
General
Age ≥60
Age ≥60 with diabetes |
<130/90
<150/90
<140/90 |
Thiazide-type diuretic, ACEI/ARB, and/or CCB
Black: avoid monotherapy with ACEI/ARB |
2019[10] |
Age <80
Age ≥80 |
<140/90
<150/90 |
Age <55: ACEI/ARB
Age ≥55 or black: CCB |
2018[11] |
Diabetes
Diabetes with CVD risk |
<140/90
<130/80 |
ACEI/ARB, thiazide-like diuretic, and/or dihydropyridine CCB |
/ 2018[12] |
General age <65
General age ≥65 |
<130/80
<140/80 |
Thiazide-type diuretic, ACEI/ARB, and/or CCB
CAD: add beta-blocker
Resistant hypertension: add spironolactone |
/ 2017[13] |
General |
<130/80 |
BP > 130/80: Lifestyle changes and monotherapy with thiazide-type diuretic, ACEI/ARB, and/or CCB
BP >20/10 above target: Lifestyle changes and two from different classes: thiazide-type diuretic, ACEI/ARB, and/or CCB |
2013[1] |
General age ≥60
General age <60
Diabetes
CKD |
<150/90
<140/90
<140/90
<140/90 |
Non-black: thiazide-type diuretic, ACEI/ARB, and/or CCB
Black: thiazide-type diuretic, and/or CCB
Diabetes: thiazide-type diuretic, ACEI/ARB, and/or CCB
CKD: ACEI/ARB |
2013[14] |
General <80 y
General ≥80 y
Diabetes
CKD |
<140/90
<150/90
<130/80
<140/90 |
General: thiazide-type diuretic, beta-blocker (age, 60 y), ACEI (non-black) or ARB
Diabetes with additional risk : ACEI/ARB
Diabetes without additional risk : ACEI/ARB, thiazide, or DHPCCB
CKD: ACEI, or ARB |
2010[15] |
Black, lower risk
Target organ damage or CVD risk |
<135/85
<130/80 |
Diuretic or CCB |